Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer

• Published in: European journal of surgical oncology Vol. 41; no. 2; pp. 228 - 235
• Main Authors: Cai, C.-Y., Zhai, L.-L., Wu, Y., Tang, Z.-G.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.02.2015
• Subjects: Adult; Area Under Curve; Biomarkers, Tumor - analysis; Biomarkers, Tumor - blood; CA-19-9 Antigen - blood; Carcinoma - blood; Carcinoma - chemistry; Carcinoma - pathology; Diagnosis; Disease-Free Survival; Female; Hematology, Oncology and Palliative Medicine; Humans; Maker; Male; Microvessels - pathology; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Pancreas - blood supply; Pancreas - chemistry; Pancreatic cancer; Pancreatic Neoplasms - blood; Pancreatic Neoplasms - chemistry; Pancreatic Neoplasms - pathology; Peroxiredoxin-1; Peroxiredoxins - blood; Peroxiredoxins - chemistry; Platelet Endothelial Cell Adhesion Molecule-1 - analysis; Prognosis; Prx-1; ROC Curve; Surgery; Survival Rate; Up-Regulation; Vascular Endothelial Growth Factor A - analysis; Peroxiredoxin-1; Prognosis; Diagnosis; Prx-1; Pancreatic cancer; Maker
• ISSN: 0748-7983; 1532-2157; 1532-2157
• DOI: 10.1016/j.ejso.2014.11.037

Peroxiredoxin-1 (Prx-1) is an important protector for redox damage and its abnormal expression is continually reported in various tumors. This study aims to investigate the expression status of Prx-1 and evaluate its clinical value in pancreatic cancer. Immunohistochemistry was used to detect Prx-1 expression in pancreatic cancer tissues and para-cancerous tissues. Enzyme-linked immunosorbent assay (ELISA) method was applied to detect the serum Prx-1 levels. The immunohistochemical results indicated that positive rate of Prx-1 was (p < 0.05) higher in pancreatic cancer tissues (74.4%) than in para-cancerous tissues (37.2%). Prx-1 expression was positively correlated with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in cancer tissues. The ELISA results showed that patients with pancreatic cancer had a higher serum Prx-1 level than healthy subjects (31.2 ± 13.5 vs. 13.2 ± 11.9 ng/ml, p < 0.001). Prx-1 expression was correlated with aggressive clinicopathological parameter. The combination of serum Prx-1 and CA19-9, the area under the curve (AUC) was significantly higher than Prx-1 separate. Positive Prx-1 expression was correlated with disappointing overall survival (OS) (p = 0.002) and disease-free survival (DFS) (p < 0.001). Multivariate analysis showed that Prx-1 staining as an independent biomarker of poor OS (p = 0.035) and DFS (p < 0.001). These findings suggest that the levels of Prx-1 expression are significantly increased in pancreatic cancer. The up-regulated Prx-1 is closely related to tumor angiogenesis and acts as a promising tumor marker for diagnosis and prognosis of pancreatic cancer.